BPM31510BPM31510-treatedMC38-CEA tumorsImmunologically cold tumors
… cell recruitment and reduced inhibitory checkpoint expression, BPM31510 creates conditions favorable for ICI response, positioning it f…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 421–480 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
OCA8Daratumumab8TCE8Sunitinib8memantine8Calprotectin8Ribociclib8Dobutamine8sulfonylurea8Entinostat8Imatinib8Encorafenib8Rifapentine8SLEDAI8Canagliflozin8Dopamine8Maralixibat8Retatrutide8Bisoprolol8Daptomycin8Etanercept8DOAC8Parecoxib8Progesterone8chloroquine8Botulinum toxin8Quetiapine8Trastuzumab deruxtecan8high-intensity statin8local anaesthetic8Magnesium8mifepristone8GLP-18Albendazole8Hypertonic saline8PBS8Valproic acid8macrolides8Interleukin-68Mounjaro8Tylenol8Ursodeoxycholic acid (UDCA)8haloperidol8tenofovir alafenamide8NIVO7Bedaquiline7Glyburide7Nerandomilast7αPD-17Axi-Cel7Terlipressin7Butyrate75-ASA7IQOS7Ofatumumab7tPA7SGLT-2 Inhibitors7BsAb7Cladribine7Curcumin7
Articles mentioning drugs
10,506 articles · page 144 of 876ST316CRCNew York Medical Collegecolorectal cancerNYMC
…N)-MDSCs in peripheral blood (PB) of phase I patients following ST316 monotherapy. Here we explore the impact of ST316 on PMN-MDSC de…
Activin AActivin A-lowPancreatic Ductal Adenocarcinoma
…lls, aSMA + CAFs, and endothelial cells additionally suggesting Activin A’s role in tumor progression. Differential gene expression analy…
dasatinibButyratedocetaxelerlotinibgefitinibTCGASTADstomach adenocarcinomaThe Cancer Genome Atlas
… patients. High-risk patients exhibited enhanced sensitivity to dasatinib, docetaxel, erlotinib, and gefitinib ( figure 1).Conclusions Th…
CLTX-CARChlorotoxinglioblastomaGBMsolid tumorsUS Food and Drug Administration
… I clinical trial evaluating the safety and feasibility of this CLTX-CAR construct in patients with recurrent or progressive MMP2+ GBM, …
AB-3028Metastatic castration-resistant prostate cancer (mCRPC)mCRPC
…ion assay, which was dependent on SPA and TGFβR2 shRNA modules. AB-3028 exhibited anti-tumor efficacy in the PC3 indication specific xe…
MICA/MICBB7-H3Pancreatic ductal adenocarcinoma (PDAC)PDAC
…sion of B7-H3 (90% ± 1.4% vs. 72% ± 6.6%, P = 0.005) and MFI of MICA/MICB (5479 ± 1680 vs. 1069 ± 691, P = 0.003), compared to non-radiat…
89.4%
DNMTiDNMTi-exposedDNMTissolid tumorshematological cancerChimeric antigen receptor (CAR) T cell therapy
…methylome and improve anti-glioma activity. We hypothesize that DNMTi treatment can enhance the immune activation and antitumor funct…
177Lu-PSMA-617cyclophosphamideCymetastatic castration-resistant prostate cancermetastatic castration-resistant prostate cancer (mCRPC)mCRPCRPTNCT03873805
…responses, and extended durability. By using the two therapies (177Lu-PSMA-617 and PSCA-CAR T cells) that are FDA approved or in clinical deve…
ipilimumabIL-2IL-2-basedmetastatic melanomaUMCGsolid tumoursendometrial cancermetastatic ovarian cancerAdoptive cell therapyendometrial cancers
…–800.Rohaan MW, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 2022;387:2113–2125.Zacha…
RD213cold tumorsAdoptive cell therapysolid tumor typesNOG micesolid tumors
…e treatment of refractory solid tumors. Clinical development of RD213 is currently underway.…
390 Hypoxia enhances the cytotoxicity of ex vivo expanded NK cells against multiple tumor cell lines
IL-15IL-2J Immunol Res
… ERK4 signaling in NK cells expanded in the presence of IL-2 or IL-15, which can enhance NK cell cytotoxicity.1 4 Here, studies by ou…